Tumor Necrosis and Cavitation after Stereotactic Body Radiation Therapy

被引：3
作者：
Devisetty, Kiran [2 ]
Salama, Joseph K. [1 ]
机构：
[1] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[2] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 07期
关键词：
CELL LUNG-CANCER; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;
D O I：
10.1097/JTO.0b013e3181d899d7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1100 / 1102
页数：3
相关论文
共 5 条
  • [1] ETTINGER DS, 2010, NCCN CLIN PRACTICE G
  • [2] Engaging the vascular component of the tumor response
    Fuks, Z
    Kolesnick, R
    [J]. CANCER CELL, 2005, 8 (02) : 89 - 91
  • [3] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    Johnson, DH
    Fehrenbacher, L
    Novotny, WF
    Herbst, RS
    Nemunaitis, JJ
    Jablons, DM
    Langer, CJ
    DeVore, RF
    Gaudreault, J
    Damico, LA
    Holmgren, E
    Kabbinavar, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191
  • [4] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Sandler, Alan
    Gray, Robert
    Perry, Michael C.
    Brahmer, Julie
    Schiller, Joan H.
    Dowlati, Afshin
    Lilenbaum, Rogerio
    Johnson, David H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) : 2542 - 2550
  • [5] Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non-Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab
    Sandler, Alan B.
    Schiller, Joan H.
    Gray, Robert
    Dimery, Isaiah
    Brahmer, Julie
    Samant, Meghna
    Wang, Lisa I.
    Johnson, David H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1405 - 1412
1